Articles related to BONE MARROW FAILURE

Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.

Srdan Verstovsek, MD, PhD of MD Anderson Cancer Center, is interviewed for answers to the questions of when to start treatment in a patient with myelofibrosis, an update on current treatment options, considerations for selecting treatment, dose optimization, sequencing of therapy, and more.

In this late-breaking abstract from the ASH Annual Meeting & Exhibition, the researches wanted to address the limited understanding of how and when CH develops, what factors govern its behavior, how it interacts with aging, and how these variables relate to malignant progression. Here are the results from analyzing 1,593 blood DNA samples from 385 elderly individuals, each sampled up to 5 times over approximately 13 years.

Bone marrow failure in children and young adults is often suspected to be inherited; however, in many cases, diagnosis remains uncertain. A new study involving 179 patients (from 173 families) found that implementing precision medicine at diagnosis can improve patient management, along with the use of family counseling. This study published in Blood expands the “portrait” of IBMF syndromes and explores some newly recognized disease entities.